High-performance liquid chromatographic determination of 17β-estradiol and 17β-estradiol-3-acetate solubilities and diffusion coefficients in silicone elastomeric intravaginal rings

被引:48
作者
Russell, JA [1 ]
Malcolm, RK [1 ]
Campbell, K [1 ]
Woolfson, AD [1 ]
机构
[1] Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland
来源
JOURNAL OF CHROMATOGRAPHY B | 2000年 / 744卷 / 01期
关键词
17; beta-estradiol; beta-estradiol-3-acetate; silicone;
D O I
10.1016/S0378-4347(00)00248-6
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A rapid, sensitive reversed-phase high-performance liquid chromatographic method has been developed for the determination of in vitro release of 17 beta-estradiol and its ester prodrug, 17 beta-estradiol-3-acetate, from silicone intravaginal rings. Partial hydrolysis of the acetate under the aqueous conditions provided by the 1% benzalkonium chloride release medium necessitates its conversion to 17 beta-estradiol prior to HPLC analysis. Both steroid peaks have been fully resolved from the benzalkonium chloride peaks by the reported chromatographic method,which employs a C-18 bonded reversed-phase column, an acetonitrile-water (50:50, v/v) mobile phase and a UV detection wavelength of 281 nm. The peak area versus 17 beta-estradiol concentration was found to be linear over the range of 0.0137-1347 mu g ml(-1) The HPLC method has also been used to determine the silicone solubilities and diffusion coefficients of the two related steroids. The almost 100-fold increase in 17 beta-estradiol-3-acetate release from the silicone core-type intravaginal rings compared to 17 beta-estradiol is shown to be due to a 60-fold increase in silicone solubility and a one and a half-fold increase in diffusitivity. The results demonstrate that an effective estrogen replacement therapy dose of 17 beta-estradiol may be administered from a silicone intravaginal reservoir device containing the labile 17 beta-estradiol-3-acetate prodrug. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:157 / 163
页数:7
相关论文
共 15 条
[1]   Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy [J].
Barentsen, R ;
vandeWeijer, PHM ;
Schram, JHN .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1997, 71 (01) :73-80
[2]  
BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062
[3]  
Chien Y. W., 1992, NOVEL DRUG DELIVERY
[4]  
CHIEN YW, 1976, CHEM PHARM BULL, V24, P1471
[5]   PHARMACOKINETICS AND PHARMACODYNAMIC EFFECTS OF VAGINAL ESTRADIOL ADMINISTRATION FROM SILASTIC RINGS IN POST-MENOPAUSAL WOMEN [J].
ENGLUND, DE ;
VICTOR, A ;
JOHANSSON, EDB .
MATURITAS, 1981, 3 (02) :125-133
[6]   HORMONE-THERAPY TO PREVENT DISEASE AND PROLONG LIFE IN POSTMENOPAUSAL WOMEN [J].
GRADY, D ;
RUBIN, SM ;
PETITTI, DB ;
FOX, CS ;
BLACK, D ;
ETTINGER, B ;
ERNSTER, VL ;
CUMMINGS, SR .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (12) :1016-1037
[7]   APPLICATION OF BETA-CYCLODEXTRIN FOR THE ANALYSIS OF ESTROGENIC STEROIDS IN HUMAN URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
LAMPARCZYK, H ;
ZARZYCKI, PK ;
NOWAKOWSKA, J ;
OCHOCKA, RJ .
CHROMATOGRAPHIA, 1994, 38 (3-4) :168-172
[8]   Estradiol delivery by vaginal rings: Potential for hormone replacement therapy [J].
Nash, HA ;
Brache, V ;
AlvarezSanchez, F ;
Jackanicz, TM ;
Harmon, TM .
MATURITAS, 1997, 26 (01) :27-33
[9]  
SESSION DR, 1993, INT J FERTIL, V38, P277
[10]   ESTRADIOL-RELEASING VAGINAL RING FOR TREATMENT OF POSTMENOPAUSAL UROGENITAL ATROPHY [J].
SMITH, P ;
HEIMER, G ;
LINDSKOG, M ;
ULMSTEN, U .
MATURITAS, 1993, 16 (02) :145-154